Voyager Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Der Gewinn von Voyager Therapeutics wird voraussichtlich um 8.1% pro Jahr zurückgehen, während der Jahresumsatz um 8.5% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 4.6% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -53% betragen.

Wichtige Informationen

-8.1%

Wachstumsrate der Gewinne

4.57%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	22.8%
Wachstumsrate der Einnahmen	8.5%
Zukünftige Eigenkapitalrendite	-52.95%
Analystenabdeckung	Good
Zuletzt aktualisiert	11 Mar 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 14

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09

Recent updates

Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet

Nov 15

Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 14

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Held Back By Insufficient Growth Even After Shares Climb 27%

Sep 25

Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)

Jun 06

It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year

May 27

Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump

Feb 25

Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance

Jan 30

Developing Tau-Targeting Therapies Will Open Doors But May Encounter Setbacks

Jan 26 Strong partnerships and collaborations are expected to enhance revenue and earnings through milestone payments and shared R&D efforts.

Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral

Nov 18

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Oct 17

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Aug 26

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Aug 08

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:VYGR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	75	-135	-119	-89	8
12/31/2027	60	-122	-110	-78	10
12/31/2026	55	-119	-104	-125	10
12/31/2025	40	-120	-135	-132	N/A
9/30/2025	31	-127	-119	-117	N/A
6/30/2025	43	-108	-116	-114	N/A
3/31/2025	67	-85	-114	-112	N/A
12/31/2024	80	-65	-19	-15	N/A
9/30/2024	164	26	-29	-25	N/A
6/30/2024	144	9	-22	-18	N/A
3/31/2024	119	-3	8	13	N/A
12/31/2023	250	132	75	78	N/A
9/30/2023	158	52	86	89	N/A
6/30/2023	195	96	91	94	N/A
3/31/2023	191	99	74	77	N/A
12/31/2022	41	-46	-15	-13	N/A
9/30/2022	71	-17	9	11	N/A
6/30/2022	31	-60	4	6	N/A
3/31/2022	32	-71	1	2	N/A
12/31/2021	37	-71	-55	-54	N/A
9/30/2021	16	-93	-92	-87	N/A
6/30/2021	132	18	-100	-91	N/A
3/31/2021	160	39	-100	-89	N/A
12/31/2020	171	37	-109	-97	N/A
9/30/2020	197	40	-110	-98	N/A
6/30/2020	100	-61	-103	-95	N/A
3/31/2020	117	-41	-113	-105	N/A
12/31/2019	104	-44	41	49	N/A
9/30/2019	74	-54	N/A	48	N/A
6/30/2019	55	-59	N/A	52	N/A
3/31/2019	12	-96	N/A	61	N/A
12/31/2018	8	-88	N/A	-16	N/A
9/30/2018	12	-78	N/A	-6	N/A
6/30/2018	11	-81	N/A	-5	N/A
3/31/2018	10	-74	N/A	2	N/A
12/31/2017	10	-71	N/A	-61	N/A
9/30/2017	6	-74	N/A	-60	N/A
6/30/2017	8	-59	N/A	-54	N/A
3/31/2017	11	-50	N/A	-47	N/A
12/31/2016	14	-40	N/A	-42	N/A
9/30/2016	17	-34	N/A	-39	N/A
6/30/2016	18	-32	N/A	-36	N/A
3/31/2016	20	-30	N/A	-33	N/A
12/31/2015	17	-38	N/A	41	N/A
9/30/2015	12	-35	N/A	46	N/A
6/30/2015	7	-32	N/A	50	N/A
3/31/2015	3	-30	N/A	55	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VYGR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VYGR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VYGR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VYGRDie Einnahmen des Unternehmens (8.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (10.4% pro Jahr).

Hohe Wachstumseinnahmen: VYGRDie Einnahmen des Unternehmens (8.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: VYGR wird voraussichtlich in 3 Jahren unrentabel sein.

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/03/11 16:54
Aktienkurs zum Tagesende	2026/03/11 00:00
Gewinne	2025/12/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, mit dem dieser Bericht erstellt wurde, sind auf unserer Github-Seite verfügbar. Außerdem bieten wir Anleitungen zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Voyager Therapeutics, Inc. wird von 26 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Brian Skorney	Baird
Jack Allen	Baird
Aydin Huseynov	Benchmark Company

Voyager Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Consensus revenue estimates fall by 44%

Consensus revenue estimates increase by 42%

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Consensus revenue estimates increase by 29%

Consensus revenue estimates fall by 21%

Recent updates

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

President notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Leadership Changes

Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet

Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Held Back By Insufficient Growth Even After Shares Climb 27%

Chief Medical Officer recently sold US$71k worth of stock

Chief Medical Officer notifies of intention to sell stock

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)

It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year

Voyager Therapeutics, Inc. Demonstrates Alpl Receptor-Mediated Blood-Brain Barrier Transport of Novel Aav Capsids in Molecular Therapy Publication

Consensus revenue estimates fall by 44%

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Voyager Therapeutics, Inc., Annual General Meeting, Jun 03, 2025

Full year 2024 earnings: EPS and revenues miss analyst expectations

Voyager Therapeutics, Inc. to Report Q4, 2024 Results on Mar 11, 2025

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease

Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump

President recently sold US$74k worth of stock

President notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 24%

Voyager Therapeutics, Inc. Provides Update on Sod1 Als Gene Therapy Program

Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance

Developing Tau-Targeting Therapies Will Open Doors But May Encounter Setbacks

New minor risk - Insider selling

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026

Investor sentiment deteriorates as stock falls 23%

Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Investor sentiment deteriorates as stock falls 19%

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Investor sentiment improves as stock rises 20%

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Consensus revenue estimates increase by 42%

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Consensus revenue estimates increase by 29%

Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting

Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold US$119k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Consensus revenue estimates fall by 21%

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Investor sentiment improves as stock rises 18%

President recently sold US$97k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research